Authors

Paul Cornes, BM, BCH, MA, MRCP, FRCR

Paul Cornes, BM, BCH, MA, MRCP, FRCR, is a consultant oncologist and biosimilars expert who was part of the team that developed and presented evidence to the FDA for the first successfullly approved US biosimilar.

Meaghan Smith

Meaghan Smith is the executive director of the Biosimilars Forum. She previously served as a senior adviser and communications director at HHS during the Obama administration.

Monica Mallampalli, PhD, MSc

Monica Mallampalli, PhD, MSc, is senior advisor for Scientific and Strategy Initiatives at HealthyWomen.

Robert Spina, MBA

Robert Spina, MBA, is vice president of Marketing, Market Access, and Patient Services at Sandoz.

Hayden E. Klein

Christopher M. Bruno, JD

Christopher M. Bruno is an associate in the Intellectual Property group at McDermott, Will, & Emery LLP, and a former law clerk of the United States Court of Appeals for the Federal Circuit and of the United States District Court for the Central District of California. With a focus on pharmaceutical patent litigation, he has litigated Hatch-Waxman Act cases from pre-complaint investigation through appeal in district courts, the Federal Circuit, the Supreme Court, and the International Trade Commission. Chris was one of the first attorneys with experience litigating the meaning of provisions of the Biologics Price Competition and Innovation Act of 2009, and he continues to play a role in decoding the relatively nascent territory of biosimilar litigation.

Bincy P. Abraham, MD

Bincy P. Abraham, MD, MS, AGAF, FACG, is a professor of Clinical Medicine at Houston Methodist Academic Institute. She is also the distinguished professor and director of the Fondren Inflammatory Bowel Disease Program at the Underwood Center for Digestive Disorders and director of Gastroenterology Fellowship Program at Houston Methodist Hospital.

Meir Rinde, MS

Meir Rinde, MS, is a freelance print and radio journalist based in Philadelphia, Pennsylvania.

Daniella (Dee) Latham